<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306681</url>
  </required_header>
  <id_info>
    <org_study_id>INS-4177</org_study_id>
    <secondary_id>U1111-1161-9157</secondary_id>
    <nct_id>NCT02306681</nct_id>
  </id_info>
  <brief_title>A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes</brief_title>
  <official_title>An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted globally. The aim of this study is to describe the proportion of
      patients with hypoglycaemic episodes and estimate the incidence of various types of
      hypoglycaemia in the retrospective and prospective periods.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2014</start_date>
  <completion_date type="Actual">May 14, 2015</completion_date>
  <primary_completion_date type="Actual">May 14, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients who experience at least 1 hypoglycaemic episode</measure>
    <time_frame>During the 4-week prospective observational period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of any hypoglycaemic episodes</measure>
    <time_frame>In the 4 weeks before and 4 weeks after the baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycaemic episodes requiring hospital admission</measure>
    <time_frame>In the 6 months before and 4 weeks after the baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypoglycaemic episodes</measure>
    <time_frame>In the 6 months before and 4 weeks after the baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-severe hypoglycaemic episodes</measure>
    <time_frame>In the 4 weeks before and 4 weeks after the baseline (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of documented symptomatic hypoglycaemic episodes</measure>
    <time_frame>In the 4 weeks after the baseline visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all hypoglycaemic episodes associated with a blood glucose measurement below 3.1 mmol/L (56 mg/dl) irrespective of symptoms</measure>
    <time_frame>In the 4 weeks following the baseline visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycaemic episodes</measure>
    <time_frame>Between midnight and 6 a.m. in the 4 weeks before and 4 weeks after the baseline visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of probable symptomatic hypoglycaemia</measure>
    <time_frame>In the 4 weeks following the baseline visit (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of blood glucose monitoring</measure>
    <time_frame>Over 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported fear of hypoglycaemia</measure>
    <time_frame>Over one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported recovery times</measure>
    <time_frame>One day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients consulting a doctor</measure>
    <time_frame>Over one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients increasing calorie intake</measure>
    <time_frame>Over one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients avoiding physical exercise</measure>
    <time_frame>Over one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reducing or skipping insulin dose</measure>
    <time_frame>Over one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients increasing the number of blood glucose monitoring as a result of fear of hypoglycaemia or hypoglycaemic episodes</measure>
    <time_frame>Over one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients taking any sick leave, sick days or short days as a result of hypoglycaemic episodes</measure>
    <time_frame>Over one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSQOLS (Diabetes-Specific Quality-of-Life Scale) scores</measure>
    <time_frame>Over last 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">7315</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>SAQ-Self-Assessment Questionnaire</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.</description>
    <arm_group_label>SAQ-Self-Assessment Questionnaire</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients with T1DM (Type 1 Diabetes Mellitus) or T2DM (Type 2 Diabetes
        Mellitus) treated with insulin for more than 12 months who are 18 years or older,
        ambulatory, literate, and have signed the Informed Consent form may participate in the
        study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities

          -  Patient with T1DM or T2DM treated with insulin for more than 12 months

          -  Male or female patient at least 18 years of age at the time of inclusion in the study

        Exclusion Criteria:

          -  Previous participation in this study

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation

          -  Illiterate patients and patients otherwise unable to sign the Informed Consent or
             complete a written survey

          -  Non-ambulatory patients

          -  Simultaneous participation in any other clinical study with an investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dhaka</city>
        <zip>1000</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <zip>1</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manilla</city>
        <zip>1605</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>2</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ajman</city>
        <zip>21499</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>Colombia</country>
    <country>Egypt</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <removed_countries>
    <country>Indonesia</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <reference>
    <citation>Faruque Pathan, Su-Yen Goh, Achmad Rudijanto, Arvind Gadekar, Anand Jain, Nemencio Nicodemus Jr. Hypoglycaemia among Insulin-Treated Patients with Diabetes: Southeast Asia Cohort of IO HAT Study Journal of the ASEAN Federation of Endocrine Societies</citation>
  </reference>
  <results_reference>
    <citation>Emral R, Pathan F, Cortés CAY, El-Hefnawy MH, Goh SY, Gómez AM, Murphy A, Abusnana S, Rudijanto A, Jain A, Ma Z, Mirasol R; IO HAT Investigator Group. Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. Diabetes Res Clin Pract. 2017 Dec;134:17-28. doi: 10.1016/j.diabres.2017.07.031. Epub 2017 Aug 9.</citation>
    <PMID>28951336</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

